


CLAIMS

1. A compound or a pharmaceutically acceptable salt thereof, which compound is:
 (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-
 5 yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one.

2. A compound or a pharmaceutically acceptable salt thereof, of Formula (IA):

(IA)



10

3. A compound as claimed in claim 2 of Formula (IA).

4. A compound of Formula (IA) as claimed in claim 3 in a crystalline form with an
 15 XRPD pattern with specific peaks at about 2-theta=20.9, 16.7, 20.2, 21.2, 27.4, 18.0, 16.8,
 23.6, 15.1 and 15.5° plus or minus 0.2° 2-theta, measured using CuK α radiation.

5. A co-crystal of the compound of Formula (IA), according to claim 3, and the co-
 former molecule 6-hydroxy-2-naphthoic acid.

20

6. A co-crystal of the compound of Formula (IA), according to claim 3, and 6-
 hydroxy-2-naphthoic acid obtainable by the steps of

i) mixing a solution of the compound of Formula (IA) in suitable solvent with 6-
 hydroxy-2-naphthoic acid co-crystal in a suitable solvent; and

25

ii) drying the resultant mixture from step (i) to obtain a solid.

7. A pharmaceutical composition comprising a compound of Formula (IA) or a

pharmaceutically acceptable salt thereof, as claimed in claim 2, and a pharmaceutically acceptable diluent or carrier.

8. A pharmaceutical composition comprising a co-crystal of the compound of
5 Formula (IA) as claimed in claim 5, and a pharmaceutically acceptable diluent or carrier.